GHRH Peptides Compared: Tesamorelin, CJC-1295, Sermorelin, Ipamorelin

What the GHRH Axis Is and Why Researchers Compare These Compounds

The GHRH axis is the upstream regulator of growth hormone (GH) release from the anterior pituitary. Native GHRH exists as GHRH(1-44)-NH₂, with a biologically active core in the first 29 residues — GHRH(1-29)-NH₂.^[2] Native GHRH is degraded rapidly in plasma — dominantly by dipeptidyl peptidase-IV (DPP-IV) cleaving at the N-terminal — and does not survive long enough for sustained signaling on its own. That degradation problem is what every modified GHRH analog is trying to solve.

Researchers compare these four compounds because they sit at different points on a structure-versus-stability curve:

• Sermorelin — unmodified GHRH(1-29). The reference compound.
• Tesamorelin — full-length GHRH(1-44) with a lipid modification that buys protease resistance.
• CJC-1295 — GHRH(1-29) with amino-acid substitutions and, in the DAC version, an albumin-binding linker that buys days of circulation time.
• Ipamorelin — not a GHRH analog. A pentapeptide GHRP that engages the ghrelin / GHS-R1a receptor on a parallel arm of the same axis.

Tesamorelin: trans-3-Hexenoyl GHRH(1-44) — What the Modification Buys

Tesamorelin is the most clinically validated compound in this group because it has an approved-product label and primary trial data behind it. The current EGRIFTA SV prescribing information describes tesamorelin as a synthetic analog of growth hormone-releasing factor (GRF), indicated for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and explicitly states that it is not indicated for weight-loss management.^[1]

Structurally, tesamorelin is GHRH(1-44)-NH₂ modified with a trans-3-hexenoyl group on the N-terminal tyrosine.^[2] Two things matter about that modification:

• It blocks the DPP-IV cleavage site that normally degrades native GHRH within minutes, increasing protease resistance.
• The lipid group adds modest serum-protein interaction, supporting a measurable plasma half-life despite the natural fragility of GHRH.

The reported terminal half-life of tesamorelin in the clinical pharmacology literature is on the order of 26 to 38 minutes after subcutaneous administration — much shorter than CJC-1295 with DAC, but long enough to drive a meaningful endogenous GH and IGF-1 response across daily dosing in the trials that supported approval.^[8]

The trial backbone for tesamorelin is the Falutz program in HIV-associated lipodystrophy, which reported significant reductions in visceral adipose tissue versus placebo over 26 weeks of daily administration.^[9] For deeper coverage of that evidence base, the dedicated Tesamorelin research review walks through the lipodystrophy, NAFLD, and 2024 label-update findings.

CJC-1295 (With and Without DAC): Albumin Binding Changes the Game

CJC-1295 is where modifications stop being incremental. The base molecule is GHRH(1-29) with four amino-acid substitutions — D-Ala², Gln⁸, Ala¹⁵, Leu²⁷ — designed to increase protease resistance.^[3] Researchers usually encounter this molecule in two distinct formats:

CJC-1295 With DAC

The "DAC" stands for Drug Affinity Complex. A maleimidopropionic acid linker is attached at the C-terminus, and that linker covalently binds to Cys34 of serum albumin after administration.^[3] Because albumin itself has a plasma half-life on the order of two to three weeks, the tethered peptide rides along with it.

In the Teichman et al. healthy-adult study, a single CJC-1295-with-DAC administration produced dose-dependent increases in mean plasma GH concentrations of roughly 2-fold to 10-fold for at least six days, increases in IGF-1 of about 1.5-fold to 3-fold for 9 to 11 days, and an estimated half-life of about 5.8 to 8.1 days.^[4] Ionescu and Frohman then showed that pulsatile GH secretion persisted during this prolonged stimulation — the compound did not collapse GH physiology into a flat continuous output.^[10]

CJC-1295 Without DAC ("Mod GRF 1-29")

The non-DAC variant has the same four substitutions but no albumin-binding linker. Without the tether, plasma half-life drops back into the ~30-minute range that the substitutions alone provide — a short-acting GHRH pulse rather than a multi-day signal.^[11]

These are two very different molecules in functional terms. "CJC-1295" without further qualification is ambiguous, and researchers reading any catalog or paper should always check whether the "with DAC" or "without DAC" format is being described. For format context, see the CJC-1295 + Ipamorelin blend Dubai page in the Remy catalog.

Sermorelin: Native GHRH(1-29) — The Unmodified Reference

Sermorelin is the unmodified parent compound — GHRH(1-29)-NH₂ with the natural human sequence, no substitutions, and no protective additions. Its job in any GHRH-axis comparison is to define the baseline.

The original prescribing information for sermorelin (Geref) reports a half-life of 11 to 12 minutes after both intravenous and subcutaneous administration in pharmacokinetic studies.^[5] Rat data from earlier work were even shorter, in the 6-minute range after IV dosing.^[12] Functionally, sermorelin produces a transient GH pulse rather than sustained stimulation — exactly what a native GHRH fragment without protease protection should do.

Sermorelin is the floor against which the other compounds in this article are measured: tesamorelin's hexenoyl modification roughly doubles to triples this half-life, CJC-1295 without DAC roughly triples it again on the back of four amino-acid substitutions, and CJC-1295 with DAC pushes from minutes into days by tethering to albumin. Each step is a structure-driven kinetic upgrade.

Ipamorelin: The GHRP That Pairs With the GHRH-Analog Story

Ipamorelin is the one compound in this set that is not a GHRH analog. It is a pentapeptide — Aib-His-D-2-Nal-D-Phe-Lys-NH₂ — from the GHRP family, acting on the ghrelin / GHS-R1a receptor rather than the GHRH receptor.^[6] The two arms converge on GH release from the same somatotrope population but through distinct intracellular pathways.

In the Raun et al. pharmacology paper, ipamorelin displayed potent GH-releasing activity in preclinical systems with relative selectivity for the somatotropic axis — releasing GH without measurable elevations of cortisol or prolactin at active doses, distinguishing it from older GHRP compounds that triggered broader pituitary responses.^[6] The follow-on human PK/PD work by Gobburu et al. described a terminal half-life of about 2 hours and a single GH-release episode peaking at roughly 0.67 hours after administration.^[7]

That mechanistic distinction is exactly why ipamorelin is so often paired with CJC-1295 in research-blend formats. The pairing is not "more of the same"; it is "two different receptor signals into one cell." For deeper component coverage, see the CJC-1295 + Ipamorelin blend guide.

How GHRH-Analog + GHRP Synergy Is Framed in Research Models

The mechanistic case for pairing a GHRH analog with a GHRP rests on a specific human physiology finding rather than on marketed-blend trials. Arvat et al. coadministered ghrelin and GHRH in healthy volunteers and observed a synergistic GH response — larger than either signal alone and larger than additive math would predict.^[13] The broader GHRH + GHRP literature, including work across age groups and metabolic states, reports the same directional finding across multiple combinations.^[14]

Two caveats for honest research framing: Arvat studied endogenous ghrelin + native GHRH, not a commercial CJC-1295 + ipamorelin product;^[13] and the synergy finding supports the concept of pairing a GHRH-receptor agonist with a ghrelin-receptor agonist without validating every claim made about specific marketed blends.

Side-by-Side: Structure, Half-Life, Mechanism

The kinetic and structural differences across the four compounds read more easily in a single table than across paragraphs:

The non-DAC CJC-1295 ("Mod GRF 1-29") variant is not in the table because functionally it sits much closer to sermorelin on the kinetic scale (~30-minute half-life range) than to CJC-1295 with DAC, despite sharing the same parent sequence.

Stability, Handling, and Research-Design Implications

Half-life differences across this group are not just a structural curiosity — they drive how researchers design preclinical work with these compounds. Minutes-scale half-life (sermorelin, CJC-1295 without DAC) means tight sampling windows around administration and frequent re-dosing for chronic exposure. Hours-scale half-life (ipamorelin, tesamorelin) means a single-pulse GH response is the dominant observation, with daily dosing intervals in supporting clinical studies. Days-scale half-life (CJC-1295 with DAC) means a single administration can drive measurable GH and IGF-1 changes over a full week, with IGF-1 readouts persisting beyond GH itself.^[4]

Storage and handling are more uniform across the group. Lyophilized GH-axis peptides are typically held refrigerated or frozen until reconstitution. After mixing with bacteriostatic water, refrigerated 2–8 °C storage is standard, with each batch's stability profile controlling the usable interval. Practical guidance lives in the bacteriostatic water guide, the peptide stability and storage guide, and the peptide interactions and mixing guide. For COA-level documentation see the COA library; for format and pack context, the Tesamorelin research vial and the full Remy catalog.

What the Literature Still Does Not Give Researchers

A serious comparison article has to be honest about its gaps. The published GHRH-axis literature is strong on individual-compound pharmacokinetics and mechanism. It is much weaker on:

• Head-to-head Phase 3 trials comparing tesamorelin, CJC-1295, sermorelin, and ipamorelin against each other on a shared clinical endpoint. They do not exist at that scale.
• Long-term safety data at the individual-compound level. Tesamorelin has the deepest dataset because of its label; the others have much thinner long-term records.
• Marketed-blend trials. Direct human efficacy trials of commercial CJC-1295 + ipamorelin blends are sparse compared with component data. The blend rationale is documented; the marketed blend itself is not.
• Cross-population generalization. Tesamorelin's evidence base is HIV-associated; sermorelin's PK comes from narrow studies; ipamorelin and CJC-1295 with DAC human work is healthy-volunteer PK/PD. Extrapolating across populations should be cautious.

Naming those gaps is the difference between a research-grade comparison and a marketing summary. For UAE compliance context, see Are peptides legal in Dubai?; for the broader landscape, the research library index.